**Participant flow diagram**

**Excluded patients**

**84**

3. Patient unable to wait on results 23

4. Antimicrobial treatment planned before surgery 1

5. Current or planned antibiotic treatment before

surgery 13

6. Surgery due to infection 7

7. Lives too far away for follow-up 12

10. Enrolled on other study 28

**Inclusion Criteria not met**

**146**

**Total Screened**

**830**

**Eligible patients**

**600**

**Consent not obtained**

**326**

A. Patient refusal 81

B. Patient incapacitated 13

C. Clinician refusal 39

D. No research staff 20

E. Lab unable to test samples 32

G. No clinical room 2

H. Too late in the day to screen 85

I. Not approached 38

J. Other 16

**Consented patients**

**274**

**Results Unknown**

**10**

Assay Failure 9

Withdrawn, not tested 1

**SA negative**

**164**

**SA positive**

**100**

**Continued on Study**

**86**

MSSA 81

MRSA 5

**Follow-up**

**86**

Lost to follow-up 0

Withdrawn 14


**Analysis**

**86**

Analysed 86

Excluded from analysis 0


**Baselinecharacteristics**



**Outcome measures**

Primary Outcome

Proportion of participants cleared of nasal SA at 48-96 hours after completing current eradication regimens for *S. aureus.*







Secondary Outcomes


**Feasibility Outcomes:**

1. Consent rates as proportion of eligible patients

2. Recruitment rates




3. Protocol Compliance rates


****

**Clinical outcomes:**


1. Clearance rates of SA from all 3 sampled sites at 48-96 hours after completing current eradication regimens for MRSA

****


2. Clearance rates of SA from all 3 sampled sites at hospital admission (pre-surgery) after completing current eradication regimens for MRSA

****

3. Clearance rates of SA from all 3 sampled sites at hospital discharge (post-surgery) after completing current eradication regimens for MRSA

****

4. Clearance rates of SA from all 3 sampled sites at 6 weeks follow-up after surgery after completing current eradication regimens for MRSA


****

5. Adverse event and serious adverse event rates – refer to next section

**Adverse Events**

There were no serious adverse events associated with this trial.

Adverse events – 5 in total described below

****